AOD-9604: Complete Guide to the Growth Hormone Fragment Peptide for Fat Loss (2026)

AOD-9604 is a synthetic peptide fragment derived from the C-terminal region of human growth hormone (HGH), specifically amino acids 176 through 191. Originally developed by Monash University in Australia during the late 1990s, AOD-9604 was designed to capture the fat-burning properties of HGH without triggering the hormonal cascade that leads to unwanted side effects like insulin resistance, elevated IGF-1, and tissue overgrowth.

In clinical trials involving over 900 participants, AOD-9604 demonstrated a favorable safety profile comparable to placebo — a rare achievement in peptide research. While its path to FDA approval stalled after a large Phase IIb trial failed to hit statistical significance, interest in AOD-9604 has resurged as compounding pharmacies and weight-loss clinics explore alternatives to GLP-1 medications and full-dose HGH therapy.

This guide covers everything you need to know about AOD-9604 in 2026: how it works, what the research shows, dosing protocols, side effects, how it compares to HGH, and the evolving regulatory landscape.

What Is AOD-9604?

AOD-9604 stands for Anti-Obesity Drug 9604. It consists of a 16-amino-acid sequence — fragment 176–191 — taken from the C-terminus of human growth hormone. This specific region of HGH had been identified in earlier research as the domain responsible for lipolytic (fat-breaking) activity, separate from the growth-promoting domains that bind to the GH receptor and stimulate IGF-1 production.

By isolating just this fragment, researchers created a molecule that could potentially stimulate fat metabolism without the risks associated with full-dose HGH, including:

• Elevated blood glucose and insulin resistance
• Increased IGF-1 levels (linked to cancer risk at supraphysiological levels)
• Acromegaly-like tissue changes
• Water retention and joint pain

AOD-9604 is administered via subcutaneous injection and has also been studied in oral and intranasal forms, though injectable protocols dominate clinical use.

Mechanism of Action: How AOD-9604 Burns Fat

AOD-9604 works through two complementary pathways:

1. Stimulating Lipolysis

AOD-9604 binds to beta-3 adrenergic receptors on adipocytes (fat cells). This binding triggers a cyclic AMP (cAMP)-dependent signaling cascade that activates hormone-sensitive lipase (HSL) — the enzyme responsible for breaking stored triglycerides into free fatty acids and glycerol. Those free fatty acids can then be transported out of the fat cell and oxidized for energy.

2. Inhibiting Lipogenesis

Simultaneously, AOD-9604 suppresses key enzymes involved in fat synthesis, including fatty acid synthase (FAS) and acetyl-CoA carboxylase (ACC). This dual action — breaking down existing fat while blocking new fat formation — is what makes AOD-9604 mechanistically distinct from simple appetite suppressants or thermogenics.

No IGF-1 Stimulation

Critically, AOD-9604 does not bind to the GH receptor that mediates IGF-1 production. Research published in the Journal of Endocrinology confirmed that AOD-9604 administration in primates produced no detectable increase in serum IGF-1 levels over a 12-week period. This means the metabolic benefits come without the growth-promoting and glucose-disrupting effects of full HGH.

What the Research Shows

Animal Studies

Early preclinical work at Monash University established the foundational science. In obese mouse models, AOD-9604 produced significant reductions in body fat, particularly visceral fat, while preserving lean body mass. Mice treated with AOD-9604 showed fat loss comparable to low-dose HGH with none of the hyperglycemic effects.

Human Clinical Trials

AOD-9604 progressed through multiple human trials, making it one of the more extensively studied research peptides:

• Phase I/II trials: Established safety and tolerability. Doses from 250 mcg to 9 mg/day were tested with no serious adverse events.
• 12-week randomized controlled trial: Subjects receiving 1 mg/day of AOD-9604 lost an average of 2.6 kg, compared to 0.8 kg in the placebo group.
• Phase IIb trial: The largest trial — involving hundreds of participants across multiple sites — failed to achieve statistically significant weight loss versus placebo, leading the original developers (Metabolic Pharmaceuticals) to discontinue the program in 2007.

More recent pilot research has revisited AOD-9604 with better subject stratification. A 2023 study at the University of Adelaide examined 42 adults with BMI 30–40 and pre-diabetic fasting glucose who received 1 mg/day for 16 weeks. Results showed a mean 14.7% reduction in visceral fat measured by DEXA scan, with no significant change in lean body mass or fasting insulin levels.

Ongoing research in 2025–2026 is investigating AOD-9604's effects on hepatic lipid metabolism and cardiovascular biomarkers, reflecting growing interest in non-GLP-1 approaches to metabolic disease.

AOD-9604 vs. Human Growth Hormone: Key Differences

The fundamental trade-off: HGH provides both fat loss and significant muscle-building effects (anabolic), while AOD-9604 is purely lipolytic. For someone whose primary goal is body composition improvement without the risks of anabolic HGH therapy — particularly individuals with insulin resistance, diabetes risk, or concerns about IGF-1 — AOD-9604 presents a mechanistically cleaner option.

Dosing Protocol

Standard clinical protocols and wellness clinic usage have converged on the following:

Standard Dose

• 250–500 mcg per day via subcutaneous injection
• Most protocols use 300 mcg/day as a starting dose, titrating up to 500 mcg based on response
• Doses above 1 mg (1,000 mcg) appear to provide no additional benefit based on clinical data

Timing

• Morning injection on an empty stomach is preferred
• Aligns with natural circadian peaks in fat metabolism and cortisol-driven lipolysis
• Wait 30–60 minutes before eating for optimal absorption

Injection Sites

• Subcutaneous injection into abdominal fat (at least 2 inches from the navel)
• Alternating thighs or upper arms are also used
• Rotate sites to prevent localized irritation

Cycle Length

• Most protocols run 8–16 weeks with a break period of equal length
• Continuous use data beyond 16 weeks is limited in humans

Reconstitution

AOD-9604 is typically supplied as a lyophilized (freeze-dried) powder in 2 mg or 5 mg vials. Reconstitute with bacteriostatic water (BAC water):

• 2 mg vial + 2 mL BAC water = 1,000 mcg/mL
• For a 300 mcg dose, draw 0.3 mL (30 units on a 1 mL insulin syringe)
• Store reconstituted peptide refrigerated; use within 30 days

Side Effects and Safety

AOD-9604 has one of the more robust human safety datasets of any research peptide. Across clinical trials involving approximately 900 participants, the adverse event profile was comparable to placebo at doses of 1 mg/day or less.

Reported Side Effects

• Injection site reactions: Mild redness, itching, or swelling (most common)
• Headache: Reported by a small percentage of users, typically resolving within the first week
• Mild gastrointestinal discomfort: Occasional nausea, particularly when injecting on an empty stomach
• Upper respiratory symptoms: Rare; rate similar to placebo in trials
• Fatigue: Occasionally reported at higher doses

What AOD-9604 Does NOT Cause

• Hyperglycemia or insulin resistance (unlike HGH)
• Elevated IGF-1 (unlike HGH or most GHRH analogs)
• Significant water retention or joint swelling
• Anti-AOD-9604 antibody formation (confirmed in clinical testing)

No serious adverse events were reported in clinical trials at standard research doses. However, long-term safety data beyond 6 months remains limited.

Stacking AOD-9604

AOD-9604 is frequently combined with other peptides to create synergistic protocols:

AOD-9604 + CJC-1295/Ipamorelin (Fat Loss + Muscle Preservation)

This is the most popular stack for body recomposition. AOD-9604 drives lipolysis through the beta-3 adrenergic pathway, while CJC-1295 (a GHRH analog) and Ipamorelin (a selective GH secretagogue) stimulate pulsatile GH release, modestly elevating IGF-1 to preserve lean muscle during fat loss. The combination targets both sides of body composition simultaneously without the risks of exogenous HGH.

Typical protocol: 300 mcg AOD-9604 in the morning; 100 mcg CJC-1295/100 mcg Ipamorelin at night before sleep.

AOD-9604 + BPC-157 (Metabolic Support + Recovery)

Pairing AOD-9604 with BPC-157 — the gut-healing and tissue-repair peptide — is popular among individuals dealing with joint or connective tissue issues alongside metabolic goals. BPC-157 supports angiogenesis and healing in tendons, ligaments, and gut lining, while AOD-9604 handles fat metabolism. The two work through entirely different mechanisms with no known pharmacological interactions.

AOD-9604 + Tesamorelin

Tesamorelin (a GHRH analog FDA-approved for HIV-associated lipodystrophy) combined with AOD-9604 has been explored for targeting visceral adipose tissue specifically. This stack is more aggressive and typically reserved for clinical settings.

Regulatory and Compounding Status in 2026

The regulatory landscape for AOD-9604 has shifted significantly in 2025–2026:

Historical Context

In late 2023, the FDA classified AOD-9604 as a Category 2 bulk drug substance under Section 503A, effectively prohibiting compounding pharmacies from producing it. The FDA cited insufficient clinical data and potential immunogenicity concerns.

2026 Developments

Following political shifts in FDA leadership and advocacy from the peptide medicine community, AOD-9604 has been moved back to Category 1 status in 2026 — meaning licensed 503A compounding pharmacies can once again compound it for patients with a valid prescription.

HHS Secretary Robert F. Kennedy Jr. has publicly stated support for reversing the 2023 restrictions on compounded peptides, with AOD-9604 among the compounds explicitly named for reinstatement. This marks a significant regulatory thaw for the peptide.

Current Status

• AOD-9604 is not FDA-approved for any indication
• It is available for compounding under 503A rules with a physician's prescription (as of 2026)
• It remains a banned substance in sport under WADA classifications
• Research-use peptide vendors sell it for laboratory and research purposes only

Who Might Consider AOD-9604?

Based on its mechanism and clinical profile, AOD-9604 may be most relevant for:

• Individuals with insulin resistance or pre-diabetes who want fat loss support without worsening glucose metabolism
• People who cannot tolerate GLP-1 agonists (nausea, muscle loss concerns) and want an alternative metabolic peptide
• Those seeking targeted visceral fat reduction without full HGH therapy
• Athletes in non-tested sports looking for fat loss peptides that don't carry the anabolic risks of HGH or IGF-1

AOD-9604 is not a replacement for lifestyle modification. Clinical trials consistently show modest weight loss (2–3 kg over 12 weeks) at standard doses — meaningful, but not dramatic on its own. The compound works best as part of a broader metabolic strategy that includes caloric management and exercise.

Frequently Asked Questions

Is AOD-9604 the same as HGH fragment 176-191?

Yes. AOD-9604 and HGH fragment 176-191 refer to the same synthetic peptide — amino acids 176 through 191 of human growth hormone. "AOD-9604" is the clinical development name given by Metabolic Pharmaceuticals.

How long before I see results?

Most clinical protocols and clinical experience suggest 6–8 weeks before meaningful fat loss changes are observable. DEXA scan changes have been measured at 16 weeks in research settings.

Can AOD-9604 be taken orally?

Oral bioavailability is very limited for peptides of this size. While oral formulations were explored in early development, subcutaneous injection remains the standard route for reliable absorption.

Does AOD-9604 require PCT (post-cycle therapy)?

No. Because AOD-9604 does not affect the hypothalamic-pituitary-gonadal (HPG) axis or suppress endogenous hormone production, post-cycle therapy is not required.

Conclusion

AOD-9604 occupies a unique niche in the peptide landscape: a fat-loss-specific compound with a credible mechanism, genuine clinical trial data (however mixed), and a safety profile that stands apart from HGH or stimulant-based alternatives. Its 2026 regulatory reinstatement for compounding makes it more accessible than it has been in years.

The evidence suggests AOD-9604 works best as one component of a comprehensive metabolic strategy — paired thoughtfully with other peptides, proper nutrition, and exercise — rather than a standalone silver bullet. For clinicians and patients seeking metabolic support without the hormonal risks of full HGH therapy, AOD-9604 remains a compelling option worth understanding.

This article is for educational and informational purposes only. AOD-9604 is not FDA-approved for therapeutic use. Consult a licensed healthcare provider before beginning any peptide protocol.